Cinctive Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Cinctive Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.42M	Buy	145,637 +104,404	+253%	+$3.37M	0.2%	162
2026 Q1	$1.31M	Buy	+41,233	New	+$1.12M	0.09%	236
2025 Q3	–	Sell	-138,040	Closed	-$2.81M	–	412
2025 Q2	$2.81M	Buy	138,040 +94,645	+218%	+$1.84M	0.15%	183
2025 Q1	$788K	Sell	43,395 -37,925	-47%	-$847K	0.06%	232
2024 Q4	$2.05M	Buy	81,320 +47,523	+141%	+$1.29M	0.1%	216
2024 Q3	$1.15M	Sell	33,797 -57,330	-63%	-$2.18M	0.06%	278
2024 Q2	$3.37M	Buy	91,127 +22,646	+33%	+$854K	0.16%	189
2024 Q1	$2.87M	Buy	+68,481	New	+$2.81M	0.13%	185

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cinctive Capital Management's CLDX Position: Q2 2026 in Review

Cinctive Capital Management increased its Celldex Therapeutics (CLDX) stake by 253% in Q2 2026, buying an estimated $3.37M and bringing the position to 145,637 shares worth $5.42M. The position accounts for 0.2% of the portfolio, ranked #162.

Cinctive Capital Management first reported a position in CLDX in Q1 2024 and has held it in 8 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Cinctive Capital Management held 145,637 shares of Celldex Therapeutics worth $5.42M as of Q2 2026.
Cinctive Capital Management bought 104,404 Celldex Therapeutics shares in Q2 2026, an estimated $3.37M.
Celldex Therapeutics made up 0.2% of Cinctive Capital Management's portfolio in Q2 2026, its #162 holding.
Cinctive Capital Management first reported a position in Celldex Therapeutics in Q1 2024 and has held it in 8 quarters since.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Cinctive Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.